# My product-operations work sample

**Ayo Ahmed - Independent concept** · **Independent concept for Semble**

> Unofficial. Synthetic operational data only. Not connected to Semble. Not a clinical system or compliance certification.

## Why I chose this problem

I designed Feedback → Release Proof to make an internal operating model concrete. I wanted one connected story from a recorded customer-facing observation to a human priority, beta exit, release decision, health signal and learning. The appointment-reminder setting is fictional; it gives the demonstration a clear operational outcome without processing patient data or making clinical decisions.

The [official Senior Product Operations Manager role](https://semble.bamboohr.com/careers/212) asks for cadence, actionable feedback, outcome tracking, release operations and measurable workflow adoption. I translated those responsibilities into a small working proposal. This sample is evidence of the concept and its demonstrated behaviour; it does not claim that I hold the role, meet location requirements, have a particular number of years' experience, or delivered unprovided professional results.

## My executive decision memo

**Recommendation:** start with a narrow, evidence-backed operating loop and test whether it improves internal decisions before expanding integrations. The first product is accountable ownership and clear gates; broader automation earns its place through measured usefulness.

**Problem hypothesis:** when source evidence, beta results and release approvals are not linked to the same scope, operators may make avoidable handoff mistakes or struggle to identify the next action. This is an independent hypothesis, not a finding about Semble.

**Proposed intervention:** preserve exact synthetic quotes; reject sensitive, invalid and duplicate evidence; require a human priority owner and measurable hypothesis; bind approvals to the feature version; and keep health response and weekly learning in the same record.

**Decision requested in a future real discovery setting:** whether the workflow merits a small internal pilot, which team owns it, and which outcome would justify keeping it. A real pilot would first establish a baseline and resolve data/privacy/security requirements. No approval, deployment or outreach is implied by this sample.

**Tradeoff:** extra evidence requirements can slow a release. I accept that friction where it prevents stale approval or unowned recovery; I would measure time spent and false blocks so the operating model does not become bureaucracy. A checklist that adds time without improving decisions should be simplified, replaced by existing tooling, or retired.

## How I made the operating model observable

I separate **what was said**, **what the simulated extractor inferred**, **what a human decided**, and **what changed after release**. A quote remains source evidence. Extraction is a draft. A priority is a human decision with an owner and hypothesis. A release signature is an attestation for one version. A health failure creates a recovery obligation. A weekly review records the next decision rather than presenting activity as impact.

I use a fixed simulation base time, `2026-10-13T09:00:00.000Z`, with deterministic one-minute steps per accepted revision to keep scenario timestamps reproducible. Synthetic beta observation days, sample sizes and rates are declared demonstration data. Test runtime is measured independently with a real elapsed-time clock. Neither synthetic timing nor runtime establishes team efficiency gains.

## What the demonstration proves and leaves open

| Evidence category | What I can say | What I cannot infer |
| --- | --- | --- |
| Public official sources | The cited role and pages advertise the responsibilities/capabilities recorded in [source-evidence.md](source-evidence.md). | Private processes, missing features, defects, endorsement or employment eligibility. |
| Working prototype | The recorded version supports a bounded synthetic feedback-to-release journey and session export. | Production readiness, verified identities, live delivery or real integrations. |
| Executed evaluation | The [test/evaluation report](test-eval-report.md) records actual checks, failures and measured runtime for the tested version. | Clinical safety, compliance, production model quality, lower defects or financial return. |
| Proposed pilot | [measurement-pilot.md](measurement-pilot.md) defines how I would establish baselines and compare outcomes. | That a baseline exists, targets have been met or operators already adopted the workflow. |

## Executed prototype evidence

The recorded run at **2026-10-13T08:54:31.922Z** passed **58/58 domain scenarios** with **171 assertions** and **31/31 HTTP integration scenarios** with **83 assertions**. The three deliberately broken-rule adapters were all detected, producing four expected red assertions separate from the passing baseline. Coverage includes failed/missing rollback rehearsal results and the health/post-review obligations before a new release cycle.

Measured local scenario execution totalled **90.274 ms** for the domain scenarios and **4,590.376 ms** for HTTP integration. These are scenario sums on the local test environment, exclude some harness startup/file-writing work, and vary between runs. They are evidence of this tested prototype's execution, not a service-level promise, production model benchmark, time saved or financial return. The [full report](test-eval-report.md) preserves expected/actual results and limitations; any later execution must be reported with its own version and timestamp.

## The package

| Artifact | Purpose |
| --- | --- |
| [PRD](prd.md) | ELI5 and 30-second explanation, jobs to be done, Five Whys hypotheses, journey, requirements and boundaries. |
| [Operating playbook](operating-playbook.md) | Ownership, cadence, OKRs, adoption and exception handling from ideation to learning. |
| [Priority memo and roadmap](priority-roadmap.md) | Transparent impact/effort decisions and a conditional 12–18 month keep/rebuild/retire plan. |
| [Measurement and pilot plan](measurement-pilot.md) | Outcome definitions, denominators, windows, baseline collection, efficiency measurement and pilot exit. |
| [Release runbook](release-runbook.md) | Human beta/release decisions, version invalidation, GTM handoff, health response and recovery. |
| [Architecture](architecture.md), [API/schema](api-schema.md) and [Threat/privacy boundaries](threat-privacy.md) | Backend enforcement and implementation trust boundaries. |
| [Evaluation](test-eval-report.md) | Executed checks and their limits. |
| [Brand guide](brand-guide.md) and [source evidence](source-evidence.md) | Original identity, exact official citations and evidence integrity. |
| [Video storyboard](video-storyboard.md) | Narrated walkthrough of the same workflow. |

## My judgement and next learning

I deliberately kept prioritisation and release human. An extracted theme can organise evidence; it cannot decide clinical or operational acceptability. I also kept a missing baseline distinct from zero. A number without a denominator or window can look persuasive while answering no useful question.

The most valuable next learning is whether operators can explain a release decision and recover from a stale or unhealthy release more reliably using this loop. I would compare that with their existing workflow, capture objections, and retire the concept if it duplicates a better system. I would expand only after evidence supports adoption and the required security/privacy controls are ready.
